Hudson Bay Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Hudson Bay Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-90,000	Closed	-$8.17M	–	398
2017 Q2	$8.17M	Buy	+90,000	New	+$8.19M	0.16%	132
2017 Q1	–	Sell	-25,000	Closed	-$2.07M	–	796
2016 Q4	$2.07M	Buy	+25,000	New	+$2.15M	0.04%	343
2015 Q4	–	Sell	-30,000	Closed	-$3.16M	–	188
2015 Q3	$3.16M	Buy	+30,000	New	+$4.01M	0.14%	98

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Hudson Bay Capital Management's BMRN Position: Q2 2026 in Review

Hudson Bay Capital Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 15% in Q2 2026, selling an estimated $8.2M and leaving 825,002 shares worth $47.2M. The position accounts for 0.13% of the portfolio, ranked #125.

Hudson Bay Capital Management first reported a position in BMRN in Q1 2015 and has held it in 46 quarters since. The position peaked at $55.1M in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Hudson Bay Capital Management held 825,002 shares of BioMarin Pharmaceuticals worth $47.2M as of Q2 2026.
Hudson Bay Capital Management sold 149,774 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $8.2M.
BioMarin Pharmaceuticals made up 0.13% of Hudson Bay Capital Management's portfolio in Q2 2026, its #125 holding.
Hudson Bay Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2015 and has held it in 46 quarters since.
Hudson Bay Capital Management's BioMarin Pharmaceuticals position peaked at $55.1M in Q1 2026.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.